Department of Biological Sciences, University of Cagliari, Italy.
Neuropharmacology. 2013 Feb;65:58-64. doi: 10.1016/j.neuropharm.2012.08.025. Epub 2012 Sep 7.
The putative 5-HT6 receptor agonist ST1936 has been shown to increase extracellular dopamine (DA) in the n.accumbens (NAc) shell and in the medial prefrontal cortex (PFCX). These observations suggest that 5-HT6 receptors modulate DA transmission in mesolimbic and mesocortical terminal DA areas. To investigate the behavioral counterpart of this interaction we studied in rats 1) the ability of ST1936 to maintain i.v. self-administration in fixed ratio (FR) and progressive ratio (PR) schedules of reinforcement; 2) the effect of 5-HT6 receptor blockade on cocaine stimulated overflow of DA in dialysates from the PFCX and from the NAc shell and on cocaine i.v. self-administration. ST1936 was i.v. self-administered at unitary doses of 0.5-1 mg/kg on an FR1 and PR schedule of reinforcement, with breaking point of about 4. Pretreatment with the 5-HT6 antagonist SB271046 reduced by about 80% responding for ST1936. SB271046 also reduced cocaine-induced increase of dialysate DA in the NAc shell but not in the PFCX and impaired i.v. cocaine self-administration. These observations indicate that ST1936 behaves as a weak reinforcer and suggest that 5-HT6 receptors play a role in cocaine reinforcement via their facilitatory interaction with DA projections to the NAc shell. This novel 5-HT/DA interaction might provide the basis for a new pharmacotherapeutic strategy of cocaine addiction.
假定的 5-HT6 受体激动剂 ST1936 已被证明可增加伏隔核(NAc)壳和内侧前额叶皮层(PFCX)中的细胞外多巴胺(DA)。这些观察结果表明,5-HT6 受体调节中边缘和中皮质末端 DA 区域的 DA 传递。为了研究这种相互作用的行为对应物,我们在大鼠中研究了 1)ST1936 在固定比率(FR)和累进比率(PR)强化方案中维持静脉内自我给药的能力;2)5-HT6 受体阻断对可卡因刺激 PFCX 和 NAc 壳透析液中 DA 溢出以及可卡因静脉内自我给药的影响。ST1936 在 FR1 和 PR 强化方案中以 0.5-1mg/kg 的单位剂量静脉内自我给药,断点约为 4。5-HT6 拮抗剂 SB271046 的预处理使 ST1936 的反应减少了约 80%。SB271046 还降低了可卡因诱导的 NAc 壳中透析液 DA 的增加,但对 PFCX 没有影响,并损害了静脉内可卡因自我给药。这些观察结果表明,ST1936 表现为一种弱的强化物,并表明 5-HT6 受体通过与 DA 投射到 NAc 壳的促进相互作用在可卡因强化中发挥作用。这种新的 5-HT/DA 相互作用可能为可卡因成瘾的新药物治疗策略提供基础。